Having purchased US$1.7m worth of Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) stock, the recent 12% pullback is not what insiders may have expected

The recent price decline of 12% in Comera Life Sciences Holdings, Inc.'s (NASDAQ:CMRA) stock may have disappointed insiders who bought US$1.7m worth of shares at an average price of US$1.34 in the past 12 months. Insiders buy with the expectation to see their investments rise in value over a period of time. However, recent losses have rendered their above investment worth US$1.3m which is not ideal.

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

Check out our latest analysis for Comera Life Sciences Holdings

The Last 12 Months Of Insider Transactions At Comera Life Sciences Holdings

The insider Charles Cherington made the biggest insider purchase in the last 12 months. That single transaction was for US$914k worth of shares at a price of US$1.23 each. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$1.05). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.

While Comera Life Sciences Holdings insiders bought shares during the last year, they didn't sell. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insiders At Comera Life Sciences Holdings Have Bought Stock Recently

Over the last quarter, Comera Life Sciences Holdings insiders have spent a meaningful amount on shares. In total, insiders bought US$1.3m worth of shares in that time, and we didn't record any sales whatsoever. This makes one think the business has some good points.

Does Comera Life Sciences Holdings Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Comera Life Sciences Holdings insiders own about US$9.8m worth of shares (which is 42% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

What Might The Insider Transactions At Comera Life Sciences Holdings Tell Us?

The recent insider purchases are heartening. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Comera Life Sciences Holdings. One for the watchlist, at least! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. To help with this, we've discovered 5 warning signs (3 can't be ignored!) that you ought to be aware of before buying any shares in Comera Life Sciences Holdings.

Of course Comera Life Sciences Holdings may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.